18:04 , Jun 19, 2019 |  BC Extra  |  Clinical News

GSK’s Rappuoli and colleagues propose model for sustainable vaccine development

A perspective article in Science Translational Medicine co-authored by GlaxoSmithKline’s Rino Rappuoli argues that to make global vaccine development sustainable, pharmas should contribute early in the process and cede late-stage testing and marketing to manufacturers...
19:57 , Jun 18, 2019 |  BioCentury  |  Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept for its modified peptide approach to killing autoimmune disease-causing cells. Announced Tuesday, the cash infusion includes €28 million ($31.4...
00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....
10:20 , Jun 13, 2019 |  BC Extra  |  Tools & Techniques

GSK teams up with Doudna, Weissman labs to create CRISPR genomics center

GlaxoSmithKline’s latest move to reinvigorate R&D is a collaboration with two of the biggest names in CRISPR research to develop new gene editing technologies and use them to identify drug targets. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
00:01 , Jun 13, 2019 |  BC Extra  |  Company News

June 12 Company Quick Takes: Macao approves Zai's Zejula; plus Roche, NIH, CVS and Dassault-Medidata

Zai obtains Zejula's approval in Macao  Zai Lab Ltd. (NASDAQ:ZLAB) said it has received approval in Macao to market PARP inhibitor Zejula niraparib to treat ovarian cancer. Zai holds its local rights from the Tesaro...
20:50 , Jun 12, 2019 |  BC Extra  |  Financial News

OrbiMed-backed Prelude raises $60M to take PRMT5 program through clinical POC

With $60 million in new series B funding, Prelude hopes to obtain clinical proof-of-concept data for its lead PRMT5 inhibitor for solid tumors or blood cancers. OrbiMed Advisors and one other undisclosed institutional investor backed...
21:27 , Jun 11, 2019 |  BC Extra  |  Company News

Ahead of Phase III data, Zai adds Deciphera's GIST candidate to gastric cancer franchise

With a Phase III readout imminent for Deciphera's kinase switch control inhibitor ripretinib in GIST, Zai Lab has obtained the compound's rights in Greater China, adding to a planned gastric cancer franchise it has built...
20:37 , Jun 7, 2019 |  BC Extra  |  Company News

June 7 Company Quick Takes: Expanded label for PTC’s DMD drug; plus Achaogen, ICER on migraine and Nucala

PTC’s DMD drug approved in patients ages 2-5  FDA approved an sNDA for Emflaza deflazacort from PTC Therapeutics Inc. (NASDAQ:PTCT) to treat Duchenne muscular dystrophy in patients ages 2-5. The drug was first approved in...
23:02 , May 30, 2019 |  BC Innovations  |  Product Development

CAR T developers plan steps to reach more indications

As CAR T developers take stock after the first wave of approvals, they are drawing a to-do list of what changes are needed to broaden the modality from its narrow indications and fully exploit its...